Freestyle libre use in people with type 2 diabetes using basal-bolus insulin is associated with improved glycaemic control: A real-world analysis.

Competing Interests: Author disclosure statement DMW: EC, SA, MRL, MC, and RR have no conflicts of interest to declare. SCB has received honoraria, teaching and research sponsorship/grants from the following: Astra-Zeneca, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Sanofi, and Takeda. SCB owns a share of Glycosmedia. These payments are not related to this work. JWS has received personal fees in relation to advisory boards and lectures for Boehringer Ingelheim, Eli Lilly, Novo Nordisk, AstraZeneca, MSD, Novo Nordisk, NAPP. These payments are not related to this work. TM reports payment or honoraria for lectures from AstraZeneca and Boehringer Ingelheim. These payments are not related to this work.